We recently published a list of Billionaire David E. Shaw’s 10 Small-Cap Stock Picks with Huge Upside Potential. In this ...

Moderna’s stock has experienced a significant decline of 12.90% over the past week, reflecting investor concerns about the company’s recent financial performance and future prospects. The ...

A combination messenger RNA vaccine against COVID-19 and seasonal influenza stacked up well against currently recommended vaccines in a phase 3 trial, according to findings published in JAMA.

A new vaccine developed by Moderna aims to protect against both flu and COVID-19 with just one shot. Early studies suggest ...

(Gray News) - A combination shot for flu and COVID-19 using messenger RNA-generated antibodies in a study, but U.S. government regulators want to see data on whether the new vaccine protects people ...

Moderna also hopes that combining the shots will help improve vaccine rates. Poland, however, is not sure people will like ...

Senior leaders at the FDA began pushing Moderna and Pfizer to file for full, formal approval of their COVID vaccines for ...

Moderna and Benchling are focused on three priorities with this digital transformation: consolidating systems to create a seamless experience for scientists, automating scientific workflows, and ...

Learn more about whether Moderna, Inc. or Avidity Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Moderna is being audited by the PMCPA after yet again being found to have brought discredit on the pharma industry, putting ...

In a study published in the Journal of the American Medical Association, researchers from Moderna reported that the new combo ...